Interaction of Pregnancy Steroid Hormones and Zidovudine in Inhibition of HIV Type 1 Replication in Monocytoid and Placental Hofbauer Cells: Implications for the Prevention of Maternal-Fetal Transmission of HIV
- 20 September 1997
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 13 (14) , 1235-1242
- https://doi.org/10.1089/aid.1997.13.1235
Abstract
Zidovudine (AZT) has been shown to reduce maternal-fetal transmission of HIV-1 by more than two-thirds in a variety of clinical settings. However, the mechanism of action of AZT in this setting is unclear. Suppression of vertical transmission has occurred in the absence of an impact on maternal plasma viremia and no lower threshold of viral load for such transmission has been identified. We hypothesized that augmentation of the anti-HIV effect of AZT may occur locally, at the maternal-fetal interface. We report that the pregnancy hormone progesterone at broad concentrations has little effect on acute HIV-1 infection of a monocytic cell line or primary peripheral blood cells. However, the combination of physiologic concentrations of progesterone (10-7 to 10-6 M) and low-dose AZT (10-8 to 10-9 M) produced markedly synergistic inhibition of HIV-1 replication within acutely infected monocytic cell lines (U937), and additive inhibition of HIV-1 growth within chronically infected monocytic cells (U1) and primary placental macrophages (Hofbauer cells). Anti-HIV effects were not seen with another pregnancy steroid hormone, estrogen. In terms of possible mechanisms of action for progesterone, we demonstrated that it incompletely suppressed tat activation of long terminal repeat (LTR)-driven gene expression in monocytic cells. However, the progesterone-mediated suppession of tat activation was not affected by mutation of the three consensus progesterone/androgen/glucocorticoid response elements within the HIV-1 LTR, previously shown by our group to be involved in glucocorticoid-mediated suppression of LTR-driven transcription. It is likely that progesterone suppresses LTR-driven gene expression through a nontranscriptional mechanism, and augments the efficacy of AZT through enhancement of its phosphorylation.Keywords
This publication has 19 references indexed in Scilit:
- Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. Effect of maternal zidovudine treatment on viral loadJAMA, 1996
- Role of Glucocorticoid Receptor Binding Sites in the Human Immunodeficiency Virus Type 1 Long Terminal Repeat in Steroid-Mediated Suppression of HIV Gene ExpressionVirology, 1995
- The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmissionAIDS, 1995
- Sustained Increases In Cd4 Cell Counts In Asymptomatic HumanThe Journal of Infectious Diseases, 1995
- Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine TreatmentNew England Journal of Medicine, 1994
- Metabolism of 3′-azido-3′-deoxythymidine (AZT) in human placentae trophoblasts and Hofbauer cellsBiochemical Pharmacology, 1994
- Human Immunodeficiency Virus Type 1 Infection of Human Placental Macrophages In VitroThe Journal of Infectious Diseases, 1993
- Pregnancy hormones, estrogen and progesterone, prevent HIV‐1 synthesis in monocytes but not in lymphocytesFEBS Letters, 1992
- HIV-1 in trophoblastic and villous Hofbauer cells, and haematological precursors in eight-week fetusesThe Lancet, 1990
- Synergistic activity of granulocyte-macrophage colony-stimulating factor and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitroAntimicrobial Agents and Chemotherapy, 1987